IN2014MN00933A - - Google Patents

Info

Publication number
IN2014MN00933A
IN2014MN00933A IN933MUN2014A IN2014MN00933A IN 2014MN00933 A IN2014MN00933 A IN 2014MN00933A IN 933MUN2014 A IN933MUN2014 A IN 933MUN2014A IN 2014MN00933 A IN2014MN00933 A IN 2014MN00933A
Authority
IN
India
Prior art keywords
insulin analogue
therapeutic agent
present
provides
preparation
Prior art date
Application number
Other languages
English (en)
Inventor
Piaoyang Sun
Lianshan Zhang
Jiajian Liu
Jijun Yuan
Chunqian Fang
Changan Sun
Hengli Yuan
Yali Wang
Original Assignee
Shanghai Hengrui Pharm Co Ltd
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Hengrui Pharm Co Ltd, Jiangsu Hengrui Medicine Co filed Critical Shanghai Hengrui Pharm Co Ltd
Publication of IN2014MN00933A publication Critical patent/IN2014MN00933A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
IN933MUN2014 2011-12-15 2012-11-22 IN2014MN00933A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201110422095 2011-12-15
PCT/CN2012/085054 WO2013086927A1 (fr) 2011-12-15 2012-11-22 Analogue d'insuline humaine et son dérivé acylé

Publications (1)

Publication Number Publication Date
IN2014MN00933A true IN2014MN00933A (fr) 2015-05-01

Family

ID=48611849

Family Applications (1)

Application Number Title Priority Date Filing Date
IN933MUN2014 IN2014MN00933A (fr) 2011-12-15 2012-11-22

Country Status (15)

Country Link
US (1) US9458219B2 (fr)
EP (1) EP2784085A4 (fr)
JP (1) JP6153206B2 (fr)
KR (1) KR20140104994A (fr)
CN (2) CN104788556A (fr)
AU (1) AU2012350586B2 (fr)
BR (1) BR112014013483A2 (fr)
CA (1) CA2858253A1 (fr)
HK (1) HK1188795A1 (fr)
IN (1) IN2014MN00933A (fr)
MX (1) MX2014006698A (fr)
RU (1) RU2014127270A (fr)
TW (1) TW201323439A (fr)
WO (1) WO2013086927A1 (fr)
ZA (1) ZA201404417B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11352406B2 (en) 2015-08-25 2022-06-07 Novo Nordisk A/S Insulin derivatives and the medical uses hereof
CN106496322A (zh) * 2015-09-07 2017-03-15 江苏恒瑞医药股份有限公司 人胰岛素或其类似物的酰化衍生物的制备方法
CN105491227A (zh) * 2015-11-20 2016-04-13 努比亚技术有限公司 一种消息排列方法和终端
EP3260548A1 (fr) 2016-06-21 2017-12-27 Enzypep B.V. Couplage enzymatique d'(oligo)peptides pour la chaîne b d'un ligand du récepteur de l'insuline
TWI747929B (zh) * 2016-08-02 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 一種人胰島素或其類似物的醯化衍生物
MX2020008129A (es) * 2018-02-01 2020-09-18 Jiangsu Hengrui Medicine Co Composicion farmaceutica que comprende un derivado acilado de un analogo de insulina humana y metodo de preparacion de la misma.
US20210032307A1 (en) * 2018-02-09 2021-02-04 Jiangsu Hengrui Medicine Co., Ltd. Codon optimized precursor gene and signal peptide gene of human insulin analogue
TW202039539A (zh) 2018-12-11 2020-11-01 法商賽諾菲公司 具有經降低胰島素受體結合親和力的胰島素類似物
CN111909255A (zh) * 2019-05-10 2020-11-10 宁波鲲鹏生物科技有限公司 胰岛素衍生物及其制备方法
JP6995284B2 (ja) 2019-12-11 2022-01-14 ノヴォ ノルディスク アー／エス 新規インスリン類似体およびそれらの使用
EP4086279A4 (fr) 2019-12-30 2024-08-07 Gan & Lee Pharmaceuticals Co Ltd Dérivé d'insuline
CN113773398B (zh) * 2020-06-10 2023-05-23 宁波鲲鹏生物科技有限公司 一种德谷胰岛素衍生物及其应用
JP2024521757A (ja) * 2021-05-24 2024-06-04 サンシャイン・レイク・ファーマ・カンパニー・リミテッド 新規なアシル化インスリンアナログ
CN118139875A (zh) 2021-06-25 2024-06-04 甘李药业股份有限公司 含酰化胰岛素的药物组合物
CN118574842A (zh) 2022-01-28 2024-08-30 甘李药业股份有限公司 酰化胰岛素

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5008241A (en) 1985-03-12 1991-04-16 Novo Nordisk A/S Novel insulin peptides
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DK257988D0 (da) 1988-05-11 1988-05-11 Novo Industri As Nye peptider
KR900701842A (ko) 1988-07-20 1990-12-04 헨리 브뢰늄 인간 인슐린 동족체와 그를 포함하는 제제
KR910700262A (ko) 1988-12-23 1991-03-14 안네 제케르 사람 인슐린 유사체
UA45321C2 (uk) * 1993-09-17 2002-04-15 Ново Нордіск А/С Похідне інсуліну, фармацевтична композиція для лікування діабету та спосіб лікування діабету
CN1195777A (zh) 1997-05-28 1998-10-14 姚维明 电力拖动实验仪
ES2307544T3 (es) * 1999-12-29 2008-12-01 Novo Nordisk A/S Metodo de produccion de precursores de insulina y analogos de precursores de insulina.
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6770625B2 (en) * 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US7193035B2 (en) 2002-10-29 2007-03-20 Sanofi-Aventis Deutschland Gmbh Crystals of insulin analogs and processes for their preparation
CN1780854A (zh) 2003-04-29 2006-05-31 伊莱利利公司 具有延长时间作用的胰岛素类似物
PL2275439T3 (pl) * 2003-08-05 2014-09-30 Novo Nordisk As Nowe pochodne insuliny
PL2107069T3 (pl) * 2003-08-05 2013-06-28 Novo Nordisk As Nowe pochodne insuliny
CN101721712A (zh) * 2008-10-21 2010-06-09 何明磊 一种双链聚乙二醇－胰岛素复合物及其制备方法

Also Published As

Publication number Publication date
JP6153206B2 (ja) 2017-06-28
BR112014013483A2 (pt) 2019-09-24
RU2014127270A (ru) 2016-02-10
EP2784085A1 (fr) 2014-10-01
EP2784085A4 (fr) 2015-07-08
CN103443122B (zh) 2016-05-11
TW201323439A (zh) 2013-06-16
MX2014006698A (es) 2014-07-09
CA2858253A1 (fr) 2013-06-20
CN103443122A (zh) 2013-12-11
AU2012350586A1 (en) 2014-07-03
ZA201404417B (en) 2016-07-27
WO2013086927A1 (fr) 2013-06-20
KR20140104994A (ko) 2014-08-29
AU2012350586B2 (en) 2017-02-02
CN104788556A (zh) 2015-07-22
US9458219B2 (en) 2016-10-04
US20140329745A1 (en) 2014-11-06
HK1188795A1 (zh) 2014-05-16
JP2015501819A (ja) 2015-01-19

Similar Documents

Publication Publication Date Title
IN2014MN00933A (fr)
ZA201505849B (en) Composition of novel carbohydrate drug for treatment of human diseases
HK1217903A1 (zh) 施用吡非尼酮療法的方法
HK1163500A1 (en) Pharmaceutical composition for the treatment of heart diseases
ZA201403795B (en) Formulations for the treatment of diabetes
EA201390796A1 (ru) Применение ацилированного аналога глюкагона
EP2677964A4 (fr) Appareil de pose de valvule cardiaque prothétique
PL2683395T3 (pl) Zastosowanie małych dawek il-2 do leczenia cukrzycy typu 1
MX349004B (es) Nuevos compuestos.
EP2782631A4 (fr) Appareil implantable utilisable en vue de l'administration d'un médicament solide-liquide, formulations associées et procédés d'utilisation
IL224544B (en) Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound
EP2623494A4 (fr) Agent pour le traitement de maladies oculaires
ZA201304822B (en) Azetidine derivatives useful for the treatment of metabolic and inflimmatory diseases
IL254446A0 (en) Implantable drug delivery preparations and treatment methods thereof
WO2012071369A3 (fr) Antagoniste rbp4 non rétinoïde pour le traitement de la dégénérescence maculaire liée à l'âge et de la maladie de stargardt
WO2014160281A3 (fr) Procédé pour améliorer l'administration de composés thérapeutiques à l'œil
AU2010286532A8 (en) Methods of treatment using anti-oxidized LDL antibodies
EP2709632A4 (fr) Compositions et procédés pour le traitement de maladies de la peau
IN2014DN03010A (fr)
WO2012123519A3 (fr) Analogues de l'insuline humaine et dérivés comprenant des substitutions de cystéine
EP2402342A4 (fr) Composition pharmaceutique servant a traiter le diabete de type 2
PL2609926T3 (pl) Zapobieganie lub leczenie bolesnej polineuropatii poprzez podawanie glikokrzemianu
HUP1100723A2 (en) Use of estrogen derivatives for preparing medicament for the treatment of psychiatric diseases
WO2011026193A8 (fr) Composés cytotoxiques
UA42333U (uk) Спосіб лікування алергічних захворювань